Press releases
Press releases dating back to 2009 are available below. Search them by keyword or browse by year/business category. Press releases for our local operating companies can be viewed on our country websites.
-
GSK’s Benlysta® (belimumab) shows sustained benefits in patients with SLE
GSK today announced results from a 7-year safety and efficacy continuation study for Benlysta® (belimumab).
Read more -
GSK leads Access to Medicine Index 2016
GSK has today been ranked first in the Access to Medicine Index for the fifth consecutive time.
Read more -
GSK announces positive results in fourth consecutive pivotal trial of Benlysta® (belimumab) in SLE
Data in Japan, China and South Korea will form basis of new regulatory submissions for Benlysta
Read more -
GSK statement in response to New York Times article on China
These matters relating to our operations in China were deeply disappointing to GSK.
Read more -
GSK presents new data for shingles candidate vaccine at IDWeek scientific conference
GSK today announced new data for its shingles candidate vaccine ShingrixTM.
Read more -
Results Announcement for the third quarter 2016
GSK delivers sales growth, improved cash flow and sustained pipeline progression in Q3.
Read more -
GSK announces US regulatory submission of candidate vaccine for prevention of shingles
Regulatory submissions in the EU and Canada remain on track for 2016
Read more -
New data published for GSK’s Nucala investigating hospitalisation reduction in severe asthma patients with an eosinophilic phenotype
The risk of hospitalisations or emergency room visits caused by asthma attacks was halved (51% reduction p<0.001) in severe asthma patients
Read more -
GlaxoSmithKline plc appoints Brian McNamara as CEO of GSK Consumer Healthcare
Brian join GSK’s Corporate Executive Team and will continue as a member of the Board of the Consumer Healthcare Joint Venture with Novartis.
Read more -
GlaxoSmithKline completes sale of remaining Aspen shares
GSK has agreed to the sale of 28.2 million ordinary shares in Aspen Pharmacare Holdings Ltd ("Aspen") at a price of ZAR 300 per share.
Read more -
GlaxoSmithKline announces intention to sell remaining holding in Aspen
GSK intends to sell its remaining stake in Aspen Pharmacare Holdings Ltd ("Aspen").
Read more -
GSK announces US regulatory submission for sirukumab in rheumatoid arthritis
Sirukumab is being co-developed for RA as part of a collaboration with Janssen Biologics (Ireland) [Janssen], an affiliate of JBI.
Read more -
GSK announces regulatory submissions for subcutaneous formulation of Benlysta® (belimumab) for patients with systemic lupus disease
It has filed regulatory submissions in the US and Europe for Benlysta® (belimumab) for approval.
Read more -
Emma Walmsley to succeed Andrew Witty as Chief Executive Officer of GlaxoSmithKline
Emma Walmsley, currently CEO of GSK’s Consumer Healthcare division, is appointed GSK CEO Designate and will succeed Andrew Witty as GSK CEO.
Read more -
GSK sets out further steps to address emerging global health security challenges
GSK will set out a series of steps to further address emerging global health challenges
Read more -
GSK’s candidate shingles vaccine shows high efficacy against shingles and its complications in adults aged 70 years and over in phase III study published in NEJM
GSK on track to file regulatory applications in 2016
Read more -
GSK announces EU regulatory submission for sirukumab in rheumatoid arthritis
Sirukumab is being co-developed for RA as part of a collaboration with Janssen Biologics (Ireland) [Janssen].
Read more -
GSK divests non-core assets to Aspen
A series of agreements Between Aspen and GSK through focusing on core therapeutic areas
Read more -
GSK presents positive results from phase III FULFIL study of closed triple combination therapy FF/UMEC/VI versus Symbicort® Turbohaler® in COPD at ERS International Congress
Improvements in lung function and health-related quality of life supported by statistically significant reductions in exacerbations
Read more -
‘Real world’ data shows 83 percent effectiveness for Bexsero® in infants in first year of UK national meningitis B immunisation programme
Cases of meningitis B halved after ten months
Read more
Find out more about us
-
About us
We are a science-led global healthcare company with a special purpose: to help people do more, feel better, live longer.
-
Products
We research and develop a broad range of innovative products in three primary areas of Pharmaceuticals, Vaccines and Consumer Healthcare
-
Research and development
Science can improve health and well-being in so many ways, from the development of everyday convenience healthcare products through to life-saving medicines and vaccines.
-
Behind the science
Explore innovations in medicines, vaccines and consumer healthcare from inside and outside our labs.
